BUSINESS OPPORTUNITIES THROUGH PARTNERSIP...
20
BUSINESS OPPORTUNITIES THROUGH PARTNERSIP WITH BIO FARMA
Transcript of BUSINESS OPPORTUNITIES THROUGH PARTNERSIP...
BUSINESS OPPORTUNITIES
THROUGH PARTNERSIP WITH
BIO FARMA
Indonesia - Demography
- Population totalling 260 million; fourth largest country in terms of population size
- Territory consists of some 13,000 islands; 60% of population confined in Java
island
- Administrative and commercial activities concentrated more in Java island
- Indonesia’s 5 biggest cities : Jakarta, Surabaya (East Java), Bandung (West
Java), Bekasi (West Java), Medan (North Sumatra)
Landscape of Indonesia’s pharmaceutical market
• Indonesia’s pharmaceutical market is the largest market in the Association of Southeast Nations (ASEAN) and is expected to reach $10.11 billion by 2021, according to GlobalData.
• The key drivers for the market are the introduction of 15 economic policy packages to attract foreign investors, the implementation of Universal Health Coverage scheme (Jaminan Kesehatan Nasional, JKN), and growing urban population.
National Industry Development
InfrastructureFood &
Agriculture
Energy & Mineral
Resources
Education Health
High Priority National Industry Development
Health is one of the high priority industries :
- Introduction of Indonesia’s Healthcare Program➢ Expand pharmaceutical market opportunities
- President’s Decree no 6/2016➢ Accelerate development of pharmaceutical industry and medical
devices in Indonesia
Indonesia’s Healthcare program
• Indonesia’s pharmaceutical sector is boosted by the establishment of a universal healthcare scheme, known as the Jaminan Kesehatan Nasional.
• This was launched in January 2014 with the aim of providing health insurance to 250 million Indonesian citizens by 2019, which would make it the world’s largest social health insurance.
President’s Decree no 6/2016(Pharmaceuticals & Medical Devices)
Sustainable in support of National Healthcare Program
Increase competitiveness among pharmas
Promote acquirement of technology and
innovation
Independency/self sufficient in
pharmaceuticals and medical devices
Aim
President’s Decree no 6/2016(Pharmaceuticals & Medical Devices)
Supporting numerous aspects including :
1. Technological advancement
➢ Biotechnology
➢ Exploration of Indonesian natural
resources
➢ Developing competence in R&D and
manufacture
2. Investments
➢ Promote local and foreign investments
3. Support healthcare program
➢ Increase access to pharmaceuticals and
medical devices
Pharma Industries
- Biotech-based
pharmas
- Biopharmaceuticals
- Biosimilars
- Mabs
- Vaccines
- Blood products
- Herbal/phytopharma
- Rapid test kits
Current Indonesia’s Pharmaceutical Industries
4 178 24No. of
manufacturers
- Bio Farma- Kimia Farma- Indo Farma- Phapros
Nawa Cita (9 priorities) State-owned companies as agents of development
President’s Decree no.6/2016 State-owned companies to increase capability in developing biopharmaceuticals, vaccines, herbals, APIs, medical devices
OVERVIEW OF BIO FARMA
Bio Farma Overview
Established in August 6, 1890
State-owned Enterprise
The number of employees approx. 1200 people
Integrated Quality System
cGMP, ISO 9001, ISO 14001, OHSAS 18001
Only manufacturer of vaccines and immunosera for human use in Indonesia
Bio Farma covers 2 sites
– Animal breeding
on the outskirts of
Bandung covering an
area of 282 441 sq
meters
– The main campus
is sited in No 28 JalanPasteur covering an area of 91 210 sq meters
• Production, QA and QC activities
• Marketing and distribution activities
• Administration
• TT Vaccine
• DT Vaccine
• DTP Vaccine
• DTP-HB Vaccine
• Td Vaccine
• BCG Vaccine
• Pentabio (DTP-HB-Hib vaccine)
• Polio Vaccine (Oral, m/b/trivalent)
• Measles Vaccine
• Hepatitis B Rec. Vaccine
• Seasonal flu vaccine
Immunosera : Tetanus, Diphtheria, Snake anti venom
List of Products
INTEGRATED MANAGEMENT SYSTEM
INTEGRATED SYSTEM
IFRS
GMP
GLP
GCP
GDPISO
9001 ISO 14001
OHSAS 18001
GCG
ERM
CSR
LIST of ProductsWHO PQ Milestones
CURRENT STATUS
BIO FARMA : State Owned Enterprise
Year Vaccine
1997 OPV, measles 10 ds
2001 DTP, DT, TT (vial)
2003 TT (Uniject)
2004 Hep B (Uniject)
2006 DTP/HepB, measles 20 ds
2009 mOPV1
2010 bOPV (1,3)
2011 Td
2014 Pentabio (DTP-HB-Hib Vaccine)
CREATING SHARED VALUE
Nawacita (9 priorities) :
Increase productivity and competitiveness in global market thus
enhancing the Indonesian people and emerge together with
other Asian countries. 3
Supplies to UN Agencies (UNICEF, PAHO), & Bilateral, 126 Countries
Polio Vaccine SupplyNo Country
1
2
3
4
5
6
7
Burkina Faso
Chad
Cote D’lvoireGambia
Guinea
MaliMauritania
9
10
11
Nigeria
Senegal
Sierra Leone
8 Niger
No Country
A
B
C
D
E
F
G
Algeria
Cote D’lvoire
GuineaMalaysia
Mozambique
TunisiaTurkey
= Unicef
= Bilateral
WHO Global Training Network : Lecturer
Third Country Training Program .
International Vaccine Institute (IVI)
• Board of Trustee
Developing Countries Vaccine Manufacturers Network
• President : 2012
Islamic Development Bank's SRVP meeting
Chairman : 2010
Actively Involved
GAVI
Board
Alternate
- Vaccines
- Immuno sera
Transition
- R&D intense
- Product diversification
- IT / ERP
- Technology
- Human Capital
- Infrastructure
Life-science- Vaccines
- Biosimilar
- MAB & Diagnos.
- Blood Product
- Stem Cell
- Animal Facility
Traditional
BIO FARMA'S BUSINESS TRANSFORMATIONBioeconomy 2030
Knowledge-based
R&D - Driven
STRATEGIC ROLE - NATIONAL and GLOBAL
BioFarma
Republic of Indonesia
WHO
(World HealthOrganization)
DCVMN(Developing Countries Vaccine Manufacturers
Network)
OIC(Organization of
Islamic Cooperation)
Secure national
vaccine supply
National life science
research forum
Fulfill vaccine needs
through WHO PQ of
vaccines
Business expansion
Joint Development
PARTNERSHIP SCHEME
Other Parties
Clinical Dev. Licensure Market
ITAGI NRA
Product Partnership
WHO PQ
AEFI Com.
Market Potential
Domestic ASEAN
OIC countries Africa
